Mesoblast Company Top Insiders
| MEOBF Stock | USD 1.90 0.55 40.74% |
Mesoblast employs about 77 people. The company is managed by 9 executives with a total tenure of roughly 180 years, averaging almost 20.0 years of service per executive, having 8.56 employees per reported executive. Examination of Mesoblast's management performance can provide insight into the company performance.
| Roger BA Insider Head Disorders |
| MS MBA Insider Chief Officer |
Mesoblast |
Mesoblast Management Team Effectiveness
The company has return on total asset (ROA) of (0.0688) % which means that it has lost $0.0688 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1581) %, meaning that it generated substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities.Mesoblast Workforce Comparison
Mesoblast is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 23,881. Mesoblast adds roughly 77.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
Mesoblast Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Mesoblast Price Series Summation is a cross summation of Mesoblast price series and its benchmark/peer.
Mesoblast Notable Stakeholders
A Mesoblast stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mesoblast often face trade-offs trying to please all of them. Mesoblast's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mesoblast's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Roger BA | Head Disorders | Profile | |
| MS MBA | Chief Officer | Profile | |
| BSc LLB | Gen Exec | Profile | |
| FACP FACRA | CEO, Founder | Profile | |
| LLB BCom | Joint Sec | Profile | |
| Justin BS | Head Manufacturing | Profile | |
| Eric MD | Chief Director | Profile | |
| Andrew BCom | Interim Officer | Profile | |
| MBA MS | Head Partnering | Profile |
About Mesoblast Management Performance
The success or failure of an entity such as Mesoblast often depends on how effective the management is. Mesoblast management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mesoblast management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mesoblast management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 77 people.
Mesoblast Workforce Analysis
Traditionally, organizations such as Mesoblast use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mesoblast within its industry.Mesoblast Manpower Efficiency
Return on Mesoblast Manpower
| Revenue Per Employee | 132.6K | |
| Revenue Per Executive | 1.1M | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 10.1M | |
| Working Capital Per Employee | 519.5K | |
| Working Capital Per Executive | 4.4M |
Complementary Tools for Mesoblast Pink Sheet analysis
When running Mesoblast's price analysis, check to measure Mesoblast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mesoblast is operating at the current time. Most of Mesoblast's value examination focuses on studying past and present price action to predict the probability of Mesoblast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mesoblast's price. Additionally, you may evaluate how the addition of Mesoblast to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |